Home Featured Page 224

Featured

Latest

Dee Dee Goldpaugh – Embracing Pleasure

Q3’25 Psychedelic Drug Development Pipeline: Bullseye Charts

‘No Prejudice, No Hype’: Florence Butlen-Ducuing on Europe’s Psychedelic Renaissance

August 2025 Psychedelic Patent Update

Unpacking FDA’s MDMA Rejection Letter and the Road Ahead for Lykos

Bright Minds Biosciences (“BMB”) Proprietary 5-HT2C Agonist Shows Significant Reduction in...

Mydecine Innovations Group signs five-year Master Collaboration Research Agreement with Johns...

How PCP Became A Weapon of Police Propaganda [Part 2]

Revive Therapeutics Signs Exclusive Worldwide License Agreement For Medicinal Mushroom Ganoderma...

Whole-Body Effects of Psychedelics Part 2 – Blood and Immune System

Psyched Wellness Submits Applications for Four Further Provisional Patents Surrounding Its...

PT258 – Manesh Girn – Psychedelics and the Brain: Neuroplasticity and...

Diamond Therapeutics Announces Health Canada Approval of Clinical Trial with Low-Dose...

Cybin Files 14th Patent Application Further Strengthening its IP Portfolio and...

MindMed Joins Critical Path Institute’s Patient-Reported Outcome Consortium

1...223224225...296 Page 224 of 296

Dee Dee Goldpaugh – Embracing Pleasure

Q3’25 Psychedelic Drug Development Pipeline: Bullseye Charts

‘No Prejudice, No Hype’: Florence Butlen-Ducuing on Europe’s Psychedelic Renaissance

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

ABOUT US

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

Dee Dee Goldpaugh – Embracing Pleasure

Q3’25 Psychedelic Drug Development Pipeline: Bullseye Charts

‘No Prejudice, No Hype’: Florence Butlen-Ducuing on Europe’s Psychedelic Renaissance

August 2025 Psychedelic Patent Update

Unpacking FDA’s MDMA Rejection Letter and the Road Ahead for Lykos

Bright Minds Biosciences (“BMB”) Proprietary 5-HT2C Agonist Shows Significant Reduction in...

Mydecine Innovations Group signs five-year Master Collaboration Research Agreement with Johns...

How PCP Became A Weapon of Police Propaganda [Part 2]

Revive Therapeutics Signs Exclusive Worldwide License Agreement For Medicinal Mushroom Ganoderma...

Whole-Body Effects of Psychedelics Part 2 – Blood and Immune System

Psyched Wellness Submits Applications for Four Further Provisional Patents Surrounding Its...

PT258 – Manesh Girn – Psychedelics and the Brain: Neuroplasticity and...

Diamond Therapeutics Announces Health Canada Approval of Clinical Trial with Low-Dose...

Cybin Files 14th Patent Application Further Strengthening its IP Portfolio and...

MindMed Joins Critical Path Institute’s Patient-Reported Outcome Consortium

EDITOR PICKS

Dee Dee Goldpaugh – Embracing Pleasure

Q3’25 Psychedelic Drug Development Pipeline: Bullseye Charts

‘No Prejudice, No Hype’: Florence Butlen-Ducuing on Europe’s Psychedelic Renaissance

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY